RAD52 and neoplasm: RAD52-mediated DNA repair remains active in PARPi-treated BRCA-deficient tumor cells such that dual inhibition of RAD52 and PARP1 have demonstrated evidence of synthetic lethality in a BRCA-deficient mouse model [69].